Psyence BioMed's Strategic Collaboration with PsyLabs Yields Breakthrough in High-Purity Ibogaine Production

Core Insights - Psyence Biomedical Ltd. announced that its strategic partner PsyLabs has successfully produced a GMP-aligned Ibogaine Total Alkaloid extract, meeting food-grade microbial safety standards verified by a third-party laboratory [1][3][4] - The company has continued its investment in PsyLabs, reflecting its commitment to supporting the development of scalable and compliant psychedelic APIs [1][4] - PsyLabs aims to further increase purity levels of its products, including Ibogaine HCL and Psilocybin Isolate, to meet growing global demand [2][4] Company Overview - PsyLabs is a federally licensed psychedelic Active Pharmaceutical Ingredient (API) development company, focusing on the cultivation, extraction, and export of various psychedelic compounds to legal medical and research markets [6][7] - The company has successfully exported psilocybin products to multiple countries, including Canada, the UK, Portugal, and Slovenia, and supplies purified extracts to its UK-based CMO partner [6][7] - Psyence Biomedical Ltd. is a vertically integrated biopharmaceutical company specializing in psychedelic-based therapeutics, being the first life sciences biotechnology company focused on nature-derived psilocybin and ibogaine to be listed on Nasdaq [7]